A His t or y of R egul at ion
Although the FDA was not known by its current name until 1930, its modern regulatory functions began with the passage of the 1906 Pure Food and Drugs Act, a law, more than a quarter of a century in the making, that prohibited interstate commerce in adulterated and misbranded food and drugs. Harvey Wiley, the chief chemist of the Bureau of Chemistry in the Department of Agriculture, had been the driving force behind the legislation, and in the early years, he headed enforcement of the law, which provided basic elements of protection that consumers had not previously known.
In 1902, one advertisement for a medical product claimed, "No other preparation has had its therapeutic value more thoroughly defined or better established . . . [as] a remedy in the treatment of coughs, bronchitis . . . asthma, laryngitis, pneumonia, and whooping cough." 1 This wonder drug was heroin -a drug that made people feel better but had an addictive potential that made its medicinal use dangerous and inappropriate.
At the turn of the 20th century, companies marketed their "patent or proprietary medicines" -some deadly, others comprising just sugar water -with a variety of unproven claims. It took decades for American medicine to emerge from what pharmacologist Louis Goodman called a "therapeutic jungle." As the years passed, important scientific advances in pharmacology, toxicology, and clinical research were central to this transformation. The FDA embraced these advancesinsisted on them, in fact -and helped pull medicine into the modern era. This effort was propelled by two critical public health events that triggered new regulatory authorities for the FDA.
In 1937, a drug company in Tennessee manufactured Elixir Sulfanilamide, sulfanilamide mixed with diethylene glycol, and although the company tested the product for flavor, appearance, and fragrance, the food and drug laws at the time did not require toxicologic analysis. As a result, more than 107 people died from ingestion of the adulterated elixir, 2 and Congress passed the Food, Drug, and Cosmetic Act the following year. The law established that drugs that are intended to prevent or treat disease must be proved to be safe for use as labeled and must include safety data from the manufacturer in the application that is submitted to the FDA. This law ended the practice of marketing new proprietary mixtures of a wide range of untested ingredients. For the first time, before pharmaceutical companies could market a drug, they had to show at least that the product was safe.
At first, it was unclear to the pharmaceutical industry, scientists, and the agency what safety really meant. Gradually, the fields of pharmacology and toxicology began to answer these questions. Standardized assessments were developed, and as these advances were incorporated into the FDA's premarket review, they became standard practice across the pharmaceutical industry.
The FDA continued to expand its regulatory scope, thanks in part to the defining case of thalidomide -the medication that was widely marketed in Europe as a sedative and antiemetic agent and was even recommended for use by women in their first trimester of pregnancy. The drug proved to be highly teratogenic. Many babies died, and thousands more were born with severe defects, including phocomelia, a devastating disorder in which the long bones of the limbs fail to develop. But the drug was never approved in the United States. Thanks to the perceptiveness and determination of a single new reviewer at the FDA, Dr. Frances Kelsey, the drug was denied approval because its sponsor failed to show basic aspects of the product's pharmacologic and toxicologic characteristics. She kept thalidomide off the market and protected the American people. 3 In a fundamental way, her actions represented the embrace of modern, innovative scientific methods.
Soon thereafter, in 1962, a pivotal regulatory advance occurred in the form of a set of amendments to the Food, Drug, and Cosmetic Actamendments that institutionalized some basic patient protections and had major consequences for the FDA and American medicine. Congress now required drug manufacturers to show substantial evidence of effectiveness and stipulated that such evidence must be based on "adequate and wellcontrolled studies." This requirement has changed the face of modern therapeutics by dramatically raising the standard of evidence and the likelihood that a marketed drug will really work.
The law emerged from broad concern over the state of the market for pharmaceuticals. At that time, companies were required to show that their products passed basic tests of safety, but there was still wide latitude for marketing a drug for many different uses, and there was no explicit standard for showing that a product did indeed do what it was supposed to do. This meant that unproven drugs at times supplanted those with known effectiveness. For example, potent psychiatric drugs were widely marketed for minor conditions. Mellaril (thioridazine, Novartis), for instance, was promoted to general practitioners for the treatment of patients with insomnia, pregnant women who were anxious about childbirth, patients with "vague digestive disorders," and "tense, nervous patients seen in everyday practice." 4 Many ineffective drugs also had serious adverse effects, subjecting patients to harm without providing any benefit. One such drug was diethylstilbestrol (DES), which was promoted to prevent miscarriage, despite a large, randomized, controlled study in 1953 showing that DES was ineffective for this use. 5 By the time the devastating, multigenerational reproductive effects of DES 6,7 became known in the 1960s and 1970s, 5 million to 10 million American women and their children had been needlessly exposed. 8 Increasingly, clinicians and pharmacology experts started to complain that there was little evidence to support the use of many medications in clinical care, which meant that the passage of the 1962 legislation marked an important change. From then on, before a drug could be marketed, the FDA had to review the manufacturers' claims and the data supporting them and conclude that effectiveness had indeed been shown.
In the case of drugs that were already on the market in 1962 and that had been approved on the basis of the FDA's prior review of their safety, sponsors now had to submit evidence of effectiveness to the agency. The FDA turned to the National Academy of Sciences for help in review- 
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ing this massive amount of information. The academy found that 70% of the claims it reviewed could not be substantiated. Almost one third of all marketed drugs lacked even a single effective use and were removed from the market entirely. 9 As the FDA set standards for effectiveness, many companies, for the first time, conducted large, randomized, controlled trials to support their claims of efficacy. Major therapeutic breakthroughs ensued, and because of the evidence now required for FDA review, the best drugs, rather than the most aggressively marketed drugs, could rise to the top. In other words, the increasingly rigorous standards of the FDA created the conditions for innovation and progress in the pharmaceutical market, and together, American medicine and the FDA have accomplished an enormous amount. Now our challenge is to continue to move forward.
L AWSui t s Thr e atening the FDA's Au thor i t y
Several recent lawsuits have challenged the FDA's authority to review the safety and effectiveness of products before they are marketed. In the first case, 10 which has now been dropped, a drug company contested the FDA's authority to require premarket review of new, "off-label" uses of drugs that have already been approved before companies may promote such uses to physicians and patients -the so-called off-label promotion issue. In the second case, tobacco companies are challenging the FDA's ability to prevent companies from marketing products with claims of reduced risk before the evidence has been reviewed. 11 In both suits, the companies argued that premarket review violates their First Amendment right to engage in free speech. According to these arguments, companies have a constitutional right to disseminate health claims about their products without first submitting evidence to the FDA showing the accuracy of those claims. The companies argue further that the FDA may step in to stop such claims only after it can produce sufficient evidence to convince a court that the claims are false or misleading. Developing such evidence would be very expensive and time-consuming, and the evidence of ineffectiveness or harm would emerge only after patients -possibly many patients -had suffered avoidable serious adverse effects. If these types of challenges are successful in obtaining the broad relief that certain companies appear to seek, they could undermine the premarket review system that has been in place for drugs since 1962 and for devices since 1976. Indeed, they place at risk efforts that are currently under way at the agency to ground FDA practices more solidly in public health practice. 12 Without question, such legal challenges, if successful, would turn back the proactive role of the FDA in American medicine, threaten current efforts to ground FDA practices in public health science, 12 and jeopardize the safety of patients, as well as the future of innovation and medical progress. Quite simply, they would ignore the lessons of history.
In the scenario sought by the plaintiffs in the first case, companies would need to generate sufficient evidence to support approval of only a single, perhaps relatively trivial, indication and would then be free to promote all other uses without any requirement to justify those uses to the agency. Under the current system, each potential use is subject to the same systematic analysis of risk versus benefit. Without the current system, companies with truly innovative and effective products could have a difficult time penetrating the confusion generated by efficacy claims made by their competitors that were not based on the kind of strict evidence that would meet the agency's current standards.
If the tobacco companies prevail in the second case, premarket approval of health claims will be abolished in its entirety (even for first indications). The pending lawsuit would leave our country vulnerable to a repeat of the "low tar" fiasco, when makers of low-delivery cigarettes urged Americans to switch to these "modified-risk" products instead of quitting, even though there was no scientific evidence that these products provided any health benefits whatsoever. design trials that answer key questions regarding safety and efficacy and insisting that all available data be provided for review. Some people who are opposed to FDA review have suggested that it should be replaced by peer review and publication in the scientific literature. Peer review is an essential part of scientific dialogue, and medical journals play a critical role in shaping the field of medical research. However, peer review is not a replacement for a strong FDA. The FDA uses multidisciplinary teamsphysicians, pharmacologists, toxicologists, chemists, and statisticians, as well as experts in the conduct of clinical trials and in the fields of clinical medicine and biopharmaceuticals, among other areas -to independently analyze the raw data from the studies. The reviewers assess the data for integrity and often conduct audits of the sponsor or clinical investigator. Peer review, on the other hand, is generally conducted by a more limited set of experts and involves only the article under consideration for publication. According to one survey, peer reviewers generally spend an average of 2 to 3 hours reviewing an article. 14 Even if peer reviewers have access to study protocols, they do not have access to the primary data, and they cannot reanalyze the original data supporting the report. In contrast, FDA reviewers have the protocols and the data at hand and may spend hundreds of hours reviewing a submission.
For many reasons, positive studies are much more likely to be published than are negative studies, although that is changing. In one study, only 43% of the trials for FDA-approved drugs were published, with larger, pivotal trials that show statistically significant results more likely to be published. 15 In another study, all but 1 of the 38 trials of antidepressant agents viewed by the FDA as having positive results were published. In contrast, of the 36 studies viewed by the FDA as having negative or questionable results, 22 were not published and 11 were reported in the literature as if they had positive results. 16 Thus, whereas FDA analyses showed that only 51% of the relevant trials were positive, physicians reading the published literature would have concluded that 94% were positive.
R egul at or y Science a nd Innovat ion
History has made the dangers of an unregulated marketplace clear. Restricting the FDA's ability to conduct premarket review would effectively set science and public health back to an earlier, more dangerous time. We must look forward to a new paradigm of scientific efforts to support innovation and medical progress. Recent scientific advances in fields as diverse as genomics and nanotechnology hold out the promise of major therapeutic breakthroughs. Yet scientific discovery is moving much faster than is the ability to translate those advances into realworld products. We are failing, as a scientific community and as a nation, to adequately deliver the promise of science to diagnose, treat, prevent, or cure disease.
We can bridge this gap, but success will require that we work together on a new set of flexible standards of product review for the 21st century through the emerging field of regulatory science. Regulatory science is the science of the assessment and evaluation of the safety, effectiveness, potency, quality, and performance of a product. We must invest in regulatory science to develop new methods, assays, standards, and models that will help speed the development, review, and approval of medical products that patients need and can rely on.
The knowledge generated from this process would inform a whole body of innovation and could help solve some of the most pressing medical and public health challenges of the 21st century. For example, before patients with Parkinson's disease can benefit from promising stem-cell therapies for restoring brain function, we must develop scientifically valid standards and manufacturing processes to ensure that the therapies are produced reliably and safely. Before we can realize the era of "personalized medicine," we need new science to identify genetic markers and subpopulations for treatment and to guide the evaluation and use of new diagnostic tests. And before we can finally cure drug-resistant tuberculosis with the use of effective combinations of drugs, we need a new pathway to evaluate earlier in the regulatory process drugs that are administered in combination.
These challenges are not the FDA's alone. To truly leverage advances in science and technology, there must be a collaboration of all relevant stakeholders, including government, academia, and industry. The FDA must work with its partners to promote innovation and creativity at various points throughout the development process. of the pipeline to approve or reject a product, the FDA can help make clinical trials more efficient by identifying qualifying biomarkers that accurately predict outcomes and by encouraging investigators to use innovative trial designs that are as effective as standard designs but less burdensome and time-consuming. And instead of accepting that the only way to test for drug safety is to expose cadres of patients to new products, the FDA can help develop innovative assays for safety that can better predict toxic effects in the liver and kidney early on. The FDA can become more transparent, so that knowledge and insights can be shared and the field of drug discovery can move forward more quickly.
Regulatory science is a field that must be widely embraced as an essential and dynamic component of the broader biomedical research enterprise. As we look to the new and emerging challenges of the 21st century, we require, now more than ever, an invested industry, an engaged academy, a strong FDA, and most of all, the recognition that together we can harness scientific progress for patients and for public health. Together, we can begin the next phase of innovation in science and medicine.
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